Page 4 - Kymab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kymab Today - Breaking & Trending Today

Y-mAbs Therapeutics' (YMAB) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $11.00 price objective on the stock. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ Q3 2023 earnings at ($0.18) EPS, Q4 2023 earnings at ($0.19) EPS […] ....

United States , New York , Capital Partners , York Life Investment Management , Y Mabs Therapeutics Inc , Morgan Stanley , Canaccord Genuity Group , Y Mabs Therapeutics Company Profile , Jump Financial , Denali Advisors , Y Mabs Therapeutics , Free Report , Genuity Group , Abs Therapeutics , Get Free Report , Y Mabs Therapeutics Daily , Nasdaq Ymab , Reiterated Rating , Hc Wainwright ,

Morgan Stanley Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $5.00

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price target decreased by stock analysts at Morgan Stanley from $7.00 to $5.00 in a research note issued on Monday, FlyOnTheWall reports. Morgan Stanley’s target price indicates a potential downside of 9.91% from the company’s previous close. YMAB has been the subject of a number of […] ....

United States , New York , Morgan Stanley , Jump Financial , Capital Partners , Denali Advisors , Canaccord Genuity Group , Y Mabs Therapeutics Inc , York Life Investment Management , Y Mabs Therapeutics , Get Free Report , Abs Therapeutics , Y Mabs Therapeutics Daily , Nasdaq Ymab , Lower Price Target ,

HC Wainwright Reaffirms "Buy" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 113.59% from the company’s current price. […] ....

United States , Metlife Investment Management , Y Mabs Therapeutics Inc , Jpmorgan Chase Co , Morgan Stanley , Canaccord Genuity Group , Blackrock Inc , Rice Hall James Associates , Swiss National Bank , Y Mabs Therapeutics , Get Free Report , Genuity Group , Abs Therapeutics Trading Down , Abs Therapeutics , Hall James , National Bank , Life Investment Management , Y Mabs Therapeutics Daily , Nasdaq Ymab , Reiterated Rating , Hc Wainwright ,

Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Thursday

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, August 10th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.24) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. Y-mAbs […] ....

United States , Johan Wedell Wedellsborg , Pricet Rowe Associates Inc , Susquehanna International Group , Algert Global , Y Mabs Therapeutics Inc , Canaccord Genuity Group , Charles Schwab Investment Management Inc , Y Mabs Therapeutics Company Profile , Securities Exchange Commission , Y Mabs Therapeutics , Get Free Report , Abs Therapeutics , Genuity Group , Director Johan Wedell Wedellsborg , Exchange Commission , Schwab Investment Management , International Group , Y Mabs Therapeutics Daily , Nasdaq Ymab ,

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $12.50 Average Price Target from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given an average rating of “Hold” by the eleven brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average […] ....

United States , Johan Wedell Wedellsborg , Tower Research Capital , Russell Investments Group Ltd , Avestar Capital , Canaccord Genuity Group , Denali Advisors , Y Mabs Therapeutics Inc , Allspring Global Investments Holdings , Y Mabs Therapeutics , Get Free Report , Abs Therapeutics , Director Johan Wedell Wedellsborg , Research Capital , Investments Group , Global Investments Holdings , Get Free , Y Mabs Therapeutics Daily , Nasdaq Ymab ,